

Physician's Name & Address:

NPI#:

DEA#:

Phone#:

Fax#:

Date:



Patient Name: _____

DOB: _____

Home Phone: _____ Cell Phone: _____ SS#: _____

Address/City/State/Zip: _____

COMPOUNDED SUBLINGUAL SEMAGLUTIDE SUSPENSION

SEMAGLUTIDE 12mg-1ml in SUBMAGNA HMW #30ml

INITIAL DOSE *This medication will NOT work if these directions are not carefully followed.* Do NOT eat or drink for at least one hour before and 30 minutes after swallowing.

Week 1: Place 0.3ml under the tongue for five minutes, or as long as possible, then swallow once daily.

Week 2: Place 0.4ml under the tongue for five minutes, or as long as possible, then swallow once daily.

Week 3: Place 0.5ml under the tongue for five minutes, or as long as possible, then swallow once daily.

TRANSITION FROM INJECTABLE DOSE *This medication will NOT work if these directions are not carefully followed.* Do NOT eat or drink for at least one hour before and 30 minutes after swallowing.

1.7mg Injectable: Place 4.8mg (0.4ml) under the tongue for five minutes, or as long as possible, then swallow once daily.

2.4mg Injectable: Place 6mg (0.5ml) under the tongue for five minutes, or as long as possible, then swallow once daily.

MAINTENANCE DOSE *This medication will NOT work if these directions are not carefully followed.* Do NOT eat or drink for at least one hour before and 30 minutes after swallowing.

Place _____ ml under the tongue for five minutes, or as long as possible, then swallow once daily.

After one month on a maintenance dose, may increase by 0.1ml as directed by the provider. Please note, titration dosing to achieve the best patient outcome is two to three months. For best results, patient hormone levels should be checked and balanced before starting sublingual Semaglutide suspension (see hormone info sheet for more information).

OTHER _____

This QR-code video link provides additional information for review.

Please feel free to share this link with other interested parties.



REFILLS: _____

PHYSICIAN'S SIGNATURE: _____ DATE: _____

Compounded sublingual Semaglutide suspension is being compounded using Semaglutide from raw material which must be refrigerated. The FDA does not review compounded medication for safety or efficacy.

This fax transmission may contain confidential information belonging to the sender, which is greatly privileged. This information is intended for the use of the recipient named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any action in reliance on the contents of this faxed information is strictly prohibited. Please notify us by phone to arrange for the return of the original documents. No claims are made as to the safety, efficacy or quality of these formulations.